- Alkhouri N, et al. (2025). Serial liver cT1 and PDFF in MASH clinical trials. Journal of Hepatology.
https://doi.org/10.1016/j.jhep.2024.08.031 - Andersson A, et al. (2022). Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clinical Gastroenterology and Hepatology.
https://doi.org/10.1016/j.cgh.2021.09.041 - Andersson A, et al. (2026). Change in cT1 following interventions in MASLD. Clinical Gastroenterology and Hepatology.
https://doi.org/10.1016/j.cgh.2025.03.003 - Banerjee R, et al. (2014). Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Journal of Hepatology.
https://doi.org/10.1016/j.jhep.2013.09.002 - Beyer C, et al. (2021). Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. PLoS One.
https://doi.org/10.1371/journal.pone.0249491 - Beyer C, et al. (2025). Quantitative MRI for monitoring MASLD (test-retest). Journal of Magnetic Resonance Imaging.
https://doi.org/10.1002/jmri.29610 - Harrison SA, et al. (2025). Pemvidutide in MASH. Journal of Hepatology.
https://doi.org/10.1016/j.jhep.2024.07.006 - Heneghan MA, et al. (2022). Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. eClinicalMedicine.
https://doi.org/10.1016/j.eclinm.2022.101325 - Imajo K, et al. (2021). Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World Journal of Gastroenterology.
https://doi.org/10.3748/wjg.v27.i7.609 - Jackson E, et al. (2025). Multiparametric MRI in MASLD. Nature Medicine.
https://doi.org/10.1038/s41591-025-03654-2 - Jayaswal ANA, et al. (2020). Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver International.
https://doi.org/10.1111/liv.14625 - Loomba R, et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa2401943 - Ndaa M, et al. (2025). Reliable monitoring of patients with metabolic dysfunction-associated steatotic liver disease using imaging: a systematic literature review and meta-analysis on measurement repeatability. Endocrine Practice.
https://doi.org/10.1016/j.eprac.2025.09.205 - Roca-Fernández A, et al. (2023). Liver disease is a significant risk factor for cardiovascular outcomes: a UK Biobank study. Journal of Hepatology.
https://doi.org/10.1016/j.jhep.2023.05.046